Furthermore, our findings indicate that Simvastatin medication was successful in suppressing LDLR-mediated tumor growth in the context of hypercholesterolemia, with lower levels of PD-L1 expression and higher levels of CD3. Here, LDLR is linked to familial hypercholesterolemia.